by Mary Stuart
The active life style and youthful appearance of many in the forty-plus age group are increasingly belied by the arm's-length...
Welcome to Medtech Insight
Create an account to read this article
Already a subscriber?
C&C Vision: Small Company, Big Vision
Presbyopia, the inability to focus close-up that come with aging, represents a blockbuster market opportunity since virtually everyone eventually suffers from the condition. The success of LASIK (laser surgery for vision correction) has created a demand on the part of patients and physicians for an alternative to glasses for the middle aged. C&C Vision hopes to be the first to offer a surgical treatment for presbyopia. Like others going after the market, however, C&C aims to validate its technology by addressing a medical need first: it is initially targeting cataracts. In doing so, however, it faces the risk of sidling up to, rather than directly attacking, the presbyopia market upon which it desires to be valued.
More from Regulation
• By
EU member states have issued a consensus statement on the urgent need to build momentum to tackle governance and centralization issues as part of much-needed reform of the EU medtech regulatory system.
• By
A recent FDA warning letter claims a Boston firm that specializes in wearable technology marketed a blood pressure device without agency approval. The company rejects the assertion and says the agency is out of step with federal law.
• By
US Medicare has proposed national coverage of renal denervation for patients with uncontrolled hypertension. The treatment is seeing other advances as well, with Medtronic piloting a longer catheter and a multi-organ approach and a blood test to identify the best candidates fresh on the
• By
Medtech companies require expertise to navigate complex AI regulations and integrate AI in medical software while addressing regulatory challenges, claims expert AI consultant with medtech experience.
More from Policy & Regulation
• By
A recent FDA warning letter claims a Boston firm that specializes in wearable technology marketed a blood pressure device without agency approval. The company rejects the assertion and says the agency is out of step with federal law.
• By
US Medicare has proposed national coverage of renal denervation for patients with uncontrolled hypertension. The treatment is seeing other advances as well, with Medtronic piloting a longer catheter and a multi-organ approach and a blood test to identify the best candidates fresh on the
• By
The US House of Representatives passes legislation requiring manufacturers of non-flushable wet wipes to label products as ‘non-flushable," a move endorsed by the Personal Care Products Council.